Introduction

The age-standardized incidence rate for pancreatic cancer (PC) in men has increased by 25% from 1957 to 2011 in Finland (http://www.cancer.fi/syoparekisteri/en/). The average age at diagnosis for PC is 69 years in Nordic males and 72 years in females. The average age at diagnosis for chronic pancreatitis (CP) is lower, 40–50 years, but there is an overlap in age, and the differential diagnosis between CP and PC can be very difficult. Clinical features, imaging changes and macroscopic appearance of CP may be difficult to differentiate from PC and a special challenge may be with paraduodenal and autoimmune pancreatitis because they closely resemble those of pancreatic ductal adenocarcinoma (PDAC).

There is no reliable non-invasive method to differentiate PC and CP at the moment and invasive methods such as needle biopsies are neither complication-free nor reliable.

The only established serum marker for pancreatic cancer is CA 19-9 with a sensitivity and specificity of 68% and 70% in differentiating between benign and malignant masses.
in the pancreas at the cutoff of 37 U/mL [1]. Increasing the cutoff increases the specificity markedly but sensitivity goes down markedly. New sensitive and specific biomarkers for differentiating these two diseases are desperately needed in the clinic. High throughput plasma proteomics can provide biomarker candidates which differentiate between the two diseases. Previously, some proteomic studies have been conducted to find biomarkers for pancreatic cancer which support and validate current study [2–6].

We have used high definition MS² (HDMS²) methodology to compare chronic pancreatitis and pancreatic cancer in serum samples. We have quantitated 291 proteins including both classes of the samples. All protein abundances were analyzed separately between the PC and CP patients. Data were further analyzed by principal component analysis (PCA) and orthogonal partial least square discriminant analysis was employed to classify the samples and find out the most significantly differing proteins between the patient groups. We propose multiple high-confidence target biomarkers which are able to classify the two diseases into separate groups.

Materials and Methods

Patient samples

Preoperative serum samples according to the routine of the hospital laboratory were collected from 22 patients with pancreatic cancer and 13 patients with chronic pancreatitis. Of the patients with pancreatic cancer, all underwent pancreaticoduodenal resection with curative intent. Of the patients with chronic pancreatitis 10 patients had alcohol-induced chronic pancreatitis and three had autoimmune pancreatitis. Six patients underwent pancreaticoduodenal resection and four patients, resection of the cauda or cauda and corpus, because malignancy could not be excluded based on preoperative investigations. In two patients the diagnosis of chronic pancreatitis was known before serum sampling. All sera were stored in aliquots of 1 mL at −80°C until used for further processing described below. The study was approved by the Surgical Ethics Committee of Helsinki University Hospital (Dnro HUS 226/E6/06, extension TMK02 §66 17.4.2013). An informed written consent was obtained from all patients.

Further processing and trypsin digestion

Serum samples were thawed and used for TOP 12 protein depletion using the TOP12 protein depletion kit (Pierce, ThermoFisher) according to the manufacturer’s instructions. Total protein concentration was determined in TOP12 protein depleted serum with Pierce BCA assay kit (Pierce, ThermoFisher). Serum equivalent to 100 μg protein was aliquoted and dried by speedvac (Savant, ThermoFisher). The resulting dried serum was dissolved 35 μL in 50 mmol/L Tris buffer, pH 7.8 containing 6M urea. After the protein dissolved, 1.8 μL of 200 mmol/L DTT was added to the samples and allowed to shake at RT for 1 h. Further, 7 μL of iodoacetamide (200 mmol/L stock solution) was added to the samples and they were further allowed to shake at RT for 1 h. After alkylation, to quench excess iodoacetamide and prevent overalkylation 7 μL of DTT (200 mmol/L) was added to samples and again shaken for 1 h at RT. Samples were diluted by adding 270 μL of MQ water and trypsin was added at 1:50 trypsin:protein ratio and digestion was allowed to occur at 37°C overnight. Following the digestion, 30 μg protein equivalent of samples were cleaned with C18 spin columns (Pierce, ThermoFisher). Resulting elution from C18 columns was dried and dissolved in 86 μL of 0.1% formic acid containing 12.5 fmol/μL of Hi3 spike-in standard peptides (Waters, MA, USA) for quantification.

Liquid chromatography-mass spectrometry (LC-MS) and quantification

UPLC-MS

A quantity of 4 μL samples (equivalent to ~1.4 μg total protein) were injected to nano Acquity UPLC (Ultra Performance Liquid Chromatography) - system (Waters Corporation, MA, USA). TRIZAIC nanoTile 85 μm × 100 mm HSS-T3u wTRAP was used for separation before mass spectrometer. Samples were loaded, trapped and washed for two minutes with 8.0 μL/min with 1% B. The analytical gradient used is as follows: 0–1 min 1% B, at 2 min 5% B, at 65 min 30% B, at 78 min 50% B, at 80 min 85% B, at 83 min 85% B, at 84 min 1% B and at 90 min 1% B with 450 nL/min. Buffer A: 0.1% formic acid in water and Buffer B: 0.1% formic acid in acetonitrile.

Data were acquired in DIA (data independent acquisition) fashion using HDMS mode with Synapt G2-S HDMS (Waters Corporation, MA, USA). The collected data range was 100–2000 m/z, scan time one-second, IMS wave velocity 650 m/s, collision energy was ramped in trap between 20 and 60 V. Calibration was done with Glu1-Fibrinopeptide B MS2 fragments and as a lock mass, Glu1-Fibrinopeptide B precursor ion was used during the runs. The samples were run as triplicates and further analysis was done with, Progenesis QI for Proteomics – software (Nonlinear Dynamics, Newcastle, UK).

Data analysis

Data analysis was performed as previously described [7]. Briefly, the raw files were imported to Progenesis QI for
Proteomic profiling of pancreatic cancer serum

M. Saraswat et al.

Proteomics software (Nonlinear Dynamics, Newcastle, UK) using lock mass correction with 785.8426 m/z, corresponding to doubly charged Glu1-Fibrinopeptide B. Default parameters for peak picking and alignment algorithm were used. The software facilitated the peptide identification with Protein Lynx Global Server and label-free quantification [8]. The peptide identification was done against Uniprot human FASTA sequences (UniprotKB Release 2015_09, 20205 sequence entries) with (CLPB_ECOLI (P63285)), ClpB protein sequence inserted for label-free quantification. Modifications used were as follows: fixed at cysteine (carbamidomethyl) and variable in methionine (oxidation). Trypsin was used as digesting agent and one missed cleavage was allowed. Fragment and peptide error tolerances were set to auto and FDR to less than 4%. One or more ion fragments per peptide, three or more fragments per protein and one or more peptides per protein were required for ion matching. These are default parameters in the software.

The identified proteins are grouped as one according to parsimony principle and also peptides unique to the protein are reported. Parsimony principle states that protein hits are reported as the minimum set that accounts for all observable peptides. Progenesis QI for proteomics does not take a strict parsimonious approach because of over-stringency as has been pointed out before [9]. However, for resolution of conflicts, if two proteins contain some common peptides, protein with fewer peptides is subsumed into the protein with higher number of peptides which are a superset of the subsumed protein’s peptides. All relevant proteins are listed as a group under the lead protein with greatest coverage or the highest score when the coverages of two or more proteins are equal. Quantitation is performed using the lead identity peptide data. More details about this approach can be found on the software website (www.nonlinear.com).

The ANOVA calculation assumes that the conditions are independent and applies the statistical test that assumes the means of the conditions are equal. The label-free protein quantitation was done with Hi-N method [8]. In every injection the sample contained also 50 fmol of six CLPB_ECOLI (P63285, ClpB protein) peptides (H13 E. coli Standard, Waters). H13 peptides are used for normalizing the peptide abundancies and relative quantitation was based on all the non-conflicting peptides found. The peptide ranking is done across all the runs. The abundancies of the peptides are averaged to provide a signal to the protein. Workings of the Progenesis softwares have been described in details on the software website (www.nonlinear.com) and also in published literature [10]. Differences between controls and cases were evaluated with ANOVA on a protein-to-protein basis. Principle component analysis was performed with Progenesis QI for proteomics. Analyse-It program (with Microsoft Excel) was used for calculating area under the curve (AUC) values of ROC curves with all the default parameters.

**Orthogonal partial least square modeling and discriminant analysis (OPLS-DA)**

OPLS-DA modeling for pancreatitis and pancreatic cancer patients was performed with rpls [11] R package. Quality metrics, variable importance in projection (VIP), permutation diagnostics (1000 random permutations) and detection of outliers were calculated within the rpls package. One predictive component and 1–4 orthogonal components were used. To find out most influential proteins for separation of patient groups, proteins with VIP>1 and univariate P-value < 0.05 adjusted for false discovery rate [12] were selected. As an alternate method to find out most influential proteins, a S-plot with loadings of each protein on the X-axis and correlation of scores to modeled X-matrix (p(corr)[1]=Corr(t1,X), t1 = scores in the predictive component) on Y-axis was constructed. Proteins with absolute value of loadings over 0.1 and absolute values of correlations over 0.7 were selected. A sample was considered as a possible outlier, if score distance exceeded SQRT(2(0.975)). The variables were standardized by mean centering and unit variance scaling. More than two unique peptide and a confidence score of more than 4.5 was required for proteins to be included in the OPLS-DA model. This filtering based on confidence score is based on previous work [13].

**Pathway analysis**

Integrated Molecular Pathway Level Analysis (IMPaLA) was used for pathway over representation analysis. The method and rationale behind the approach has been published previously [14]. By default, if no background list is supplied, the software uses all the entities present in all the pathways as background. Ingenuity pathway analysis (Ingenuity Systems, Redwood City, CA) was used for performing core analysis on the proteomic dataset with default parameters of the software. The results (canonical pathways) are presented in the results section as a figure. All the identified proteins were fed into IPA as input.

**Data repository**

The raw files were converted with MSConvert (Proteowizard) to mzML-files. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE [15] partner repository with the dataset identifier PXD005144.
Results

Metadata
Twenty two pancreatic cancer and 13 chronic pancreatitis samples were analyzed in this study. In the CP group, three patients had autoimmune pancreatitis, and 10 had alcohol-induced chronic pancreatitis. Age of the patients in the PC group ranged from 54 to 79 and in the CP group from 42 to 74. Complete clinical features of the patients including grade of the tumor, T and N stage, gender and age are given in Table S1. One of the samples (autoimmune pancreatitis) was excluded from the analysis (due to technical reasons) as the chromatographic alignment of the technical replicates was not good and it stacked further aside from other samples in the PCA. This sample is marked in the Table S1.

Protein identification
We analyzed PC and CP samples by HDMSE and quantified 653 proteins from serum including proteins with minimum one unique peptide. Two hundred and ninety proteins were quantified with two or more unique peptides. Confidence score of identification ranged from 4084.212 to 3.913. Only 11 proteins had the confidence score less than 4.6. Fold changes ranged from 1369.4 to 1.001 when PC has the higher mean and 236.5 to 1.004 when CP had the higher mean. One protein was found only in CP and five only in PC. Hundred and sixty-four proteins passed the cutoff of 0.05 of ANOVA P value when the higher mean was set to CP and 102 when the higher mean was set to PC. The complete data of all the proteins including various parameters such as ANOVA P values are given in Table S2. Our main criterion for differing proteins between the two classes was ANOVA P values and many proteins have P values higher than 0.05 despite having big fold change. Such proteins are not considered to be different.

Principal component analysis (PCA)
PCA was performed using the software Progenesis QI for Proteomics. This analysis determines the main axis of variation in the quantities of individual proteins which can point out the outliers. This method is also suitable to study the technical replicates as they should be close to each other on the PCA biplot. PCA biplot can tell the difference between amounts of variation among two classes of samples and present it in a visual manner. PCA of these CP and PC is shown in Figure 1.

The upper panel in the Figure 1 is the PCA when all the proteins were considered for PCA, and it can be seen that samples already have the tendency to cluster into two classes. Some overlapping samples can also be seen between the two groups but majority of the samples from the two groups (CP and PC) fall apart on the biplot. When only the housekeeping proteins (fold change 1 to 1.3) were considered for PCA (middle panel) there is an almost complete overlap between the two groups which is expected as these proteins do not differ much between the two classes. Further, when only the proteins, having ANOVA P values lower than 0.05 and fold change more than 2, were considered for PCA there is a clear separation of the two groups with only very few samples falling in the overlapping area. The better than moderate separation of PC and CP patients in PCA prompted us to delve deeper into the statistical analysis and we constructed a model which is described in the next section.

Orthogonal partial least square modeling and discriminant analysis (OPLS-DA)
OPLS method enables distinct modeling of the predictive or correlated variance to the factor of interest as well as the uncorrelated variance. OPLS is an extension of the PLS statistical modeling but performs better in terms of interpreting the data from the model [11]. It is particularly useful when the number of variables exceeds the number of samples and when there is multicollinearity among the variables. For constructing an OPLS-DA model, ropls package in “R” was used and as a first step the data was filtered. For the filtering of proteins, stringent parameters were used such as; only the proteins with more than two peptide count and more than two unique peptides with confidence score cutoff of 4.5 were considered for OPLS-DA modeling. These proteins are given in Table S3.

Multivariate model was built, using OPLS in ropls package, for each protein’s abundance. The scores plot for the model is shown in the Figure 2A. The model was built with one predictive and one orthogonal component. Black ellipse is the 95% confidence interval for the model and red and blue ellipses are the 95% of multivariate normal distribution for each class of samples.

Permutation testing was employed to establish the significance of the R2Y and Q2Y values (Figure S1) and P values for both parameters can be found on the top of the graph (both being significant). Diagnostic plot (Figure S2) was used to highlight the observations to find out the samples which are further away from the projection plane.

Cutoff for the score distance is the vertical dotted line and patient numbered C10 and ×1 appear to be outliers (Figure 2A). These two samples are marked in the Table S1 in the remarks column, which is patient information table. To further assess whether the quality of the model (or fit, R2Y) or separation between the classes (Q2Y) can
be improved by removing the outliers, these two samples were removed and model was built again. After removing these two outliers, the model was built again and this time we called it improved model. Figure 2B shows the scores plot and the permutation testing is shown in Figure S1 of the rebuilt, Improved model.

For cross-validation, 80% of the data was used for the training of the model and 20% for the prediction, averaging over 1000 randomly chosen training and prediction sets. We calculated the sensitivity and specificity of the prediction in the improved model using this approach and it was found to be 94% (95% CI: 93–95%) and 67% (95% CI: 65–68%), respectively. In the training series or in the full model sensitivity and specificity were both 100%.

To find out the proteins of interest, which were significant sources of variation between the two classes, two approaches were taken (univariate vs. multivariate parameters plot and S-Plot). P value for the false discovery rate (pFDR, univariate parameter) and variable influence on projection (VIP, multivariate parameter) were calculated for all the proteins and plotted against each other (Fig. 3). To validate this list of significantly different proteins and to find the variable proteins by another method S-Plot was constructed (Fig. 4).

Nineteen significant proteins were found by pFDR versus the VIP plot in the initial model and 18 in the improved model. Fifteen proteins were found to be significant in the improved model S-Plot (Table 1). Most proteins were common in all three methods and can be seen in the Table 1.

Pathway analysis

Two tools were employed for pathway analysis namely IMPaLA and Ingenuity pathway analysis (IPA). Figure S3
shows the pathway over-representation analysis by IMPaLA in two conditions; when the highest mean was set to CP and when the highest mean was set to PC. Only the pathways with P\textsubscript{genes} and Q\textsubscript{genes} values below 0.05 were considered and Figure S3 shows the top 10 pathway enriched in both the lists of proteins. Various complement activation and coagulation pathways were the main pathways enriched in both the lists. However, P\textsubscript{genes} and Q\textsubscript{genes} values were better in PC list for these pathways compared to CP list. Fibrinolytic pathways were particular enriched in CP and not in PC list. In IPA core analysis, top biofunctions and diseases are shown in Figure S4. Inflammatory response, developmental disorder and immunological diseases were the top disorders enriched and cellular movement and lipid metabolism were among the top molecular functions enriched.

In the same analysis by IPA, multiple canonical pathways were enriched in the CP and PC proteomic dataset. These were LXR/RXR activation, acute phase signaling response and similar to IMPaLA analysis, complement and coagulation system. Some of the top canonical pathways are shown in Figure 5.

**Receiver operating characteristic (ROC) curves**

Proteins found most significantly different in initial and improved OPLS-DA model and S-Plot of OPLS-DA model were further used for ROC Curve analysis. This method
was utilized to validate the diagnostic value of the proteins found common to all three methods, results of which are presented in Table 1. All these proteins were compared with each other to get a list of unique proteins and common to all three techniques. These proteins were analyzed by ROC curve analysis and area under the curve (AUC), 95% confidence interval and standard error were calculated as described in methods. The results are presented in Table 2. The Highest AUC value was found for protein AMBP (AUC: 0.951) followed by Inter-alpha-trypsin inhibitor heavy chain H2 (AUC: 0.947). The lowest AUC for the proteins analyzed by ROC curve was for protocadherin alpha-13, which was 0.841 which is also good value for AUC. These proteins can classify the samples into two categories by various methods.

**Discussion**

Pancreatic cancer is the eighth leading cause of death worldwide in men and ninth in women [16]. The incidence rates are slightly higher in western industrialized world and lower in developing countries such as India and Nigeria. Cancer statistics have revealed that prognosis of pancreatic cancer has not improved in recent years (judged by the survival of the patients) compared to other carcinomas [17]. Late diagnosis and aggressive nature of the cancer are responsible for the poor prognosis of PC. Delay in diagnosis is due to the several reasons including the prominent lack of suitable screening markers in an asymptomatic population.

CA 19-9 and carcinoembryonic antigen (CEA) are the two most used serum biomarkers in PDAC, but are not suitable for screening an asymptomatic population [18, 19]. They further have inadequate accuracy, even for primary diagnosis of symptomatic patients [18, 19]. Low sensitivity of the test necessitates invasive confirmatory examinations to confirm diagnosis. CA 19-9 displays sensitivity of 68% at 37 U/mL [1] and CEA 45%[20] and specificity of 70% and 81%, respectively [1, 20], figures that are too low for differential diagnosis from CP. It has to be noted that different studies report different values of sensitivity for CA 19-9 due to the differential cutoff values used. CA19-9 is now mainly accepted only as a follow-up and prognostic biomarker. Different types of CP cases closely resemble PC in clinical and imaging features and there is urgent need for novel biomarkers for differential and early diagnosis.

Serum is attractive for discovering screening and other type of biomarkers as it reflects organ-originated physiological changes [21] and is easy to collect. Dynamic range of protein concentration in plasma or serum is $10^9$ [22] and top 12 proteins constitute >95% of total plasma/serum proteins. For this reason, it is very difficult to identify the low-abundant proteins which are potential biomarkers of various diseases. It is desirable to deplete high-abundant proteins to enable relatively deeper analysis of the serum proteome in health and disease. Twelve CP and 22 PC patients were retrospectively recruited for this study and serum protein profiles were studied by HDMS E using Synapt G2S HDMS system. After depletion of the top 12 most abundant proteins in human serum as described in methods, we quantified 291 proteins. However, Out of the total proteins identified, only some proteins (with peptide count of 2 or more and 2 or more unique peptides with confidence score of at least 4.5) were used for OPLS-DA modeling. R package ropls was employed to this end and data was normalized as described in methods. PCA visually presents the principal axes of variation in samples which helps in interpreting the separation of the groups. However, PCA with outliers present can give false results or lead to incorrect interpretations in classification of the samples. OPLS-DA scores plot and diagnostic plot can easily spot outliers in the data. These outliers, if included in the modeling reduce the optimum fit of the model to the data and lower the predictive accuracy of the statistical model. We found two outliers in the data and they were removed and the model was built again. This exercise markedly improved the
separation quality of the model. These outliers performed normally as technical replicates however, the standardized expression profile for one of these samples (C10) was the highest in its group (Pancreatic cancer) and the other sample (×1) had the lowest expression profile in its group (Chronic pancreatitis). It could have been the reason for them to perform differently from the rest of the samples. Proteins of interest were found in the initial model by pFDR versus the VIP plot (univariate) and in improved model by univariate as well as multivariate manner (S-Plot). Most of the proteins found were common to all three lists suggesting that these proteins are the main sources of variation among the two disease groups. It also suggests that these two methods are complementary to each other for feature selection in OMICS data which is in accordance with published literature [11].

Acylglycerol kinase, mitochondrial (AGK), is a lipid kinase which converts mono- and diacylglycerol to lysophosphatidic acid (LPA) and phosphatidic acid (PA) respectively [23]. Increase in LPA results in transactivation of epidermal growth factor receptor (EGFR) which leads to increased cell proliferation [23]. Overexpression of AGK can drive cancer cell growth and play an important role in pathophysiology of cancer [23]. Protein AMBP was another protein which was commonly found in all two models and all three methods of feature selection to be significantly different (Table 1). It has previously been found to be increased in pancreatic cancer [24]. However, there is no study hinting at its pathophysiological role in PC or CP. AMBP is an acute phase protein like others found in our study to be significantly different between PC and CP such as afamin, hemopexin and inter alpha-trypsin inhibitor heavy chain (ITIH) H1, H2, and H3. Acute phase response (APR) is critical for our bodies to respond to injury. However, sustained APR can lead to development of chronic inflammation and tissue injury eventually giving rise to diseases such as cancer. Acute phase proteins also increase the blood flow to the site of injury [25] which can be hijacked by tumor microenvironment as a strategy to get access to sustained blood flow and nutrients. Therefore, acute phase proteins such as those found in our study are not bystanders but potentially active players in tumorigenesis. They can make suitable biomarkers but it has to be considered with caution as they go up in several other conditions as well [26, 27]. Acute phase proteins may also reflect systemic inflammatory response seen in some of the cancer patients. For example, preoperative systemic inflammatory response (elevated CRP) in PDAC is an indicator of poor prognosis [28]. Preoperative CRP levels are also strong predictors of survival in colon cancer [29] and colorectal liver metastases [30]. Another protein found in all three methods of feature selection was Hepatocyte growth factor which is a ligand for c-MET. Cells in tumor microenvironment overexpress HGF and cancer cells have increased expression of c-MET and these events lead to promotion of various cancer-driving pathways [31, 32]. Our study gives insight into the biology of events driving the sustained growth and invasion of pancreatic cancer. Differential proteomics combined with statistical/mathematical analysis can provide biomarker candidates and also targets for therapeutic modulation of diseases. Two of the proteins, protein AMBP and ITI-H2 are known to be modified by chondroitin sulfate [33] and linked to each other. In protein AMBP, we have identified peptides which belong to only the Trypsatin part of the protein. Trypsatin is a separate chain which is a monomer. We did not identify any peptide from other parts of the protein AMBP (Bikunin) which, considering the limitations of the technological workflow used, excludes the possibility that we quantified the complex of ITI-H2 heavy and light chain. In case of ITI-H2, we have identified peptides only from the mature part of the chain while the chondroitin sulfated peptide is in propeptide region from which we did not identify any peptide. This again, despite the limitations, excludes the possibility that we have quantified the ITI-H2 complex with light chain bound via chondroitin sulfate.

In the context of published literature, the study by Pan et al. quantified four plasma biomarkers of PC namely, 14-3-3 sigma, gelsolin, lumican and tissue inhibitor of metalloproteinase 1 (TIMP-1)[34]. When compared to our dataset, 14-3-3 sigma and TIMP-1 were not identified in our study. The reason is the low concentration of these two proteins (approximately 50 ng/mL for 14-3-3 sigma and 700 nag/mL for TTIMP-1). The other two proteins gelsolin and lumican were confidently identified in our study. In the study by Pan et al. gelsolin had a fold change (FC) of 3.4 in PC versus CP and our study has the FC of 1.3 in PC vs CP. It was significantly different in both the studies (T-test in Pan et al. and Mann–Whitney test in our study). However, Lumican, having the FC of 1.18 in our study (PC vs. CP) and 2.62 in Pan et al. (PC vs. CP) was not found to be significantly different in our study by Mann–Whitney test. It is to be noted that it was significantly different in our study by T-test but not by Mann–Whitney test. Pan et al. did the T-test for finding significance among the differences. Non-normal distribution dictates the use of non-parametric test and because of this reason, Mann–Whitney test was used in our study. Careful choice of statistical tests allows for more robust data analysis and chance of finding real differences are increased. However, none of these proteins passed the significance in OPLS-DA modeling as being significantly different proteins. T-test is a univariate method of data analysis while modern day proteomics datasets are more amenable to multivariate data analysis such as
Table 1. Selection of significantly different proteins.

| Uniprot Accessions | Protein Name | PFDR | VIP  |
|--------------------|--------------|------|------|
| P02760;S4R471      | Protein AMBP | 0.0003 | 2.1372 |
| P19823;A0A087WTE1;Q5T985 | Inter-alpha-trypsin inhibitor heavy chain H2 | 0.0005 | 1.9313 |
| P15313;C9JL73;C9JZ02 | V-type proton ATPase subunit B, kidney isoform | 0.0009 | 1.9485 |
| P26927;H7C0F8      | Hepatocyte growth factor-like protein | 0.0021 | 2.2957 |
| P36955;I3L107;I3L1U4;I3L2R7;I3L3Z3;I3L425;I3L4F9;I3L4N7;I3L4Z0 | Pigment epithelium-derived factor | 0.0021 | 1.7997 |
| P04217             | Alpha-1B-glycoprotein | 0.0034 | 1.5699 |
| P00734;C9JV37;E9PT3 | Prothrombin | 0.0043 | 1.6451 |
| P19827;F8WAS2;H7C0N0;H7C510 | Inter-alpha-trypsin inhibitor heavy chain H1 | 0.0043 | 1.9809 |
| P01024;E9P9V1;E9PR27;M0QYC8;O95568 | Complement C3 | 0.0069 | 1.6420 |
| P05155;H0YCA1;H9KV48 | Plasma protease C1 inhibitor | 0.0086 | 1.9650 |
| P05156;D6R928;E7ETH0;G3XAM2 | Complement factor I | 0.0107 | 1.7204 |
| Q81VV2;H7BZ41;I3QKK9 | Lipoxynase homology domain-containing protein 1 | 0.0161 | 1.7367 |
| Q6ZRR7;H3BUS4      | Leucine-rich repeat-containing protein 9 | 0.0161 | 1.7785 |
| P43652             | Afamin | 0.0161 | 1.8528 |
| P02790;Q9BS19;Q9NPA0 | Hemopexin | 0.0241 | 1.8158 |
| Q9C099             | Leucine-rich repeat and coiled-coil domain-containing protein 1 | 0.0291 | 1.3278 |
| P02743             | Serum amyloid P-component | 0.0291 | 1.6691 |
| P02749;J3KS17;J3QL10;J3QRN2 | Beta-2-glycoprotein 1 | 0.0291 | 1.7742 |
| E9PG39;E9PC15;Q53H12 | Acylglycerol kinase, mitochondrial | 0.0424 | 1.5528 |

The OPLS-DA model was built initially and again after removing two outliers found in the initial model. Variable influence on projection (VIP) values were plotted against P value for the false discovery rate (pFDR) and significantly different proteins between the two disease conditions were selected by choosing a cutoff of 0.05 for pFDR and 1 for VIP. These proteins as well as the proteins found to be significantly different by S-Plot (P 1 cutoff value of 0.1 and P (Corr) [1] value of 0.7) are presented in the table with appropriate parametric values given for each protein.
to be able to classify CP versus PC samples in another study [38]. Another study identifying fucosylated proteins as candidate biomarkers for PC versus CP classification found 14 proteins common with our study [39]. These proteins are Plasma protease C1 inhibitor, hemopexin, Alpha-1B-glycoprotein, Inter-alpha-trypsin inhibitor heavy chain H2 and H1, Complement C5, Serum amyloid P-component, Complement factor I, Protein AMBP, Beta-2-glycoprotein 1, Prothrombin, Pigment epithelium-derived factor, Afamin and Complement C3. Other proteins suggested as candidate biomarkers in our study such as Hepatocyte growth factor-like protein and Acylglycerol kinase, mitochondrial among others are novel and presented for the first time to the best of our knowledge.

### Table 1.

| Protein Name                                      | pFDR  | VIP    | Uniprot Accessions                                                                 | Protein Name                                      | P1       | P_corr(1) |
|---------------------------------------------------|-------|--------|-----------------------------------------------------------------------------------|---------------------------------------------------|----------|-----------|
| Alpha-1B-glycoprotein                             | 0.0008| 1.8576 | Q8IVV2;H7BZ41;J3QKX9                                                             | Lipoxygenase homology domain-containing protein 1 | −0.1170  | −0.9794   |
| Prothrombin                                       | 0.0008| 2.0369 | P26927;H7C0F8                                                                    | Hepatocyte growth factor-like protein              | −0.1330  | −0.9445   |
| Protein AMBP                                      | 0.0012| 2.1869 | P15313;C9JL73;C9Z02                                                              | V-type proton ATPase subunit B, kidney isform      | 0.1370   | 0.9313    |
| Inter-alpha-trypsin inhibitor heavy chain H2      | 0.0012| 2.2491 | P00734;C9JY37;E9PT3                                                               | Prothrombin                                       | 0.1200   | 0.8766    |
| V-type proton ATPase subunit B, kidney isoform    | 0.0029| 2.3420 | P05156;D6R9Z8;E7ETH0;G3XAM2                                                        | Complement factor I                                | 0.1150   | 0.8704    |
| Hemopexin                                         | 0.0039| 2.1569 | P02743                                                                          | Serum amyloid P-component                          | 0.1300   | 0.8326    |
| Pigment epithelium-derived factor                 | 0.0067| 2.0018 | P43652                                                                          | Afamin                                            | 0.1130   | 0.8184    |
| Hepatocyte growth factor-like protein              | 0.0086| 2.2709 | P01031                                                                          | Complement C5                                      | 0.1080   | 0.8001    |
| Inter-alpha-trypsin inhibitor heavy chain H1      | 0.0086| 2.2428 | Q9Y510;C9JA99;D6RA20;Q9UN74;Q9UN75;Q9Y5H5;Q9Y5H7;Q9Y5H8;Q9Y5H9;Q9Y5I3;Q9Y5I4 | Protopsiderin alpha-13                            | 0.1060   | 0.7860    |
| Serum amyloid P-component                          | 0.0110| 2.2131 | P19823;A0A087WTE1;Q5T985                                                          | Inter-alpha-trypsin inhibitor heavy chain H2       | 0.1320   | 0.7748    |
| Complement C3                                      | 0.0110| 1.9340 | P36955;I3L107;I3L1U4;I3L2R7;I3L3Z3;I3L425;I3L4F9;I3L4N7;I3L4Z0                   | Pigment epithelium-derived factor                  | 0.1170   | 0.7672    |
| Acylglycerol kinase, mitochondrial                 | 0.0139| 1.8189 | P19827;F8WAS52;H7C0N0;H7C510                                                       | Inter-alpha-trypsin inhibitor heavy chain H1       | 0.1320   | 0.7499    |
| Inter-alpha-trypsin inhibitor heavy chain H3      | 0.0139| 1.8199 | P02749;J3KS17;J3QL1O;J3QRN2                                                        | Beta-2-glycoprotein 1                              | 0.1150   | 0.7322    |
| Leucine-rich repeat-containing protein 9           | 0.0276| 1.8487 | P02760;S4R471                                                                    | Protein AMBP                                       | 0.1280   | 0.7236    |
| Complement factor I                                | 0.0276| 1.9549 | P02790;Q98519;Q9NPA0                                                              | Hemopexin                                         | 0.1270   | 0.7193    |
| Beta-2-glycoprotein 1                              | 0.0341| 1.9661 |                                                                                 |                                                   |          |           |
| Plasma protease C1 inhibitor                       | 0.0341| 1.8136 |                                                                                 |                                                   |          |           |
| Afamin                                            | 0.0422| 1.9287 |                                                                                 |                                                   |          |           |
Pathway analysis mainly yielded the complement and coagulation cascades as enriched suggesting that they are the main perturbed pathways. Tissue factor, plasminogen and thrombin are the main coagulation-related proteins increased in PC [40–42]. Such a situation will lead to hypercoagulability-like state which is frequently observed in PC. It has been previously shown that thrombin:antithrombin complex and prothrombin fragment 1 + 2 are increased in CP compared to healthy individuals but they are lower than in PC [43]. We have found, in our dataset, that prothrombin is increased in PC compared to CP with significant ANOVA P-value. In the OPLS-DA analysis the P value was also found to be significant for this protein ($P = 0.00087$ i.e., $P < 0.001$, see Table 1). Moreover, the prothrombin:antithrombin ratio in our dataset in was 0.29 in CP while it was 0.34 in PC which, in the form of a trend, agrees well with the literature [43]. Our pathway analysis results show that P and Q values for coagulation pathways were much stronger for PC compared to CP. It could be a continuous phenomenon and with increasing inflammation the thrombin levels are increased and become highest for PC. In such a case, an optimum cutoff value can differentiate PC from CP. Accordingly, AUC for thrombin was found to be 0.917 which is one of the highest in our dataset.

Figure 5. Canonical pathways enriched by core analysis in IPA. Top canonical pathways enriched by Ingenuity Pathway Analysis “Core analysis” are shown here. Straight orange vertical line running through the bars is threshold for P value for the particular pathway’s enrichment. Horizontal axis is the $–\log (P\text{ value})$ and vertical axis represents the given pathways.
In conclusion, we report a number of potential biomarkers with good statistical significance which can be used to differentiate PC versus CP. This is one of the most cumbersome and difficult clinical decisions in certain age groups. This pilot research paves the way for further studies to capitalize on the potential of the current one.

Acknowledgments

Authors thank Helsinki University Hospital and Sigrid Jusélius Foundation for financial support.

Conflict of Interest

Authors declare no conflict of interest.

References

1. Bedi, M. M. S., M. D. Gandhi, G. Jacob, V. Lekha, A. Venugopal, and H. Ramesh. 2009. CA 19-9 to differentiate benign and malignant masses in chronic pancreatitis: is there any benefit? Indian J. Gastroenterol. 28:24–27.

2. Koomen, J. M., L. N. Shih, K. R. Coombes, D. Li, L. C. Xiao, I. J. Fidler, et al. 2005. Plasma protein profiling for diagnosis of pancreatic cancer reveals the presence of host response proteins. Clin.Cancer Res. 11:1110–1118.

3. Hanas, J. S., J. R. Hocker, J. Y. Cheung, J. L. Larabee, M. R. Lerner, S. A. Lightfoot, et al. 2008. Biomarker identification in human pancreatic cancer sera. Pancreas 36:61–69.

4. Deng, R., Z. Lu, Y. Chen, L. Zhou, and X. Lu. 2007. Plasma proteomic analysis of pancreatic cancer by 2-dimensional gel electrophoresis. Pancreas 34:310–317.

5. Ansari, D., R. Andersson, M. P. Bauden, B. Andersson, J. B. Connolly, C. Welinder, et al. 2015. Protein deep sequencing applied to biobank samples from patients with pancreatic cancer. J. Cancer Res. Clin. Oncol. 141:369–380.

6. Pan, S., R. Chen, D. A. Crispin, D. May, T. Stevens, M. McIntosh, et al. 2011. Protein alterations associated with pancreatic cancer and chronic pancreatitis found in human plasma using global quantitative proteomics profiling. J. Proteome Res. 10:2359–2376.

7. Saraswat, M., S. Joenväärä, T. Jain, A. K. Tomar, A. Sinha, S. Singh, et al. 2016. Human spermatozoa quantitative proteomic signature classifies normo- and asthenozoospermia. Mol. Cell Proteomics mcp. M116.061028.

8. Silva, J. C., M. V. Gorenstein, G.-Z. Li, J. P. C. Vissers, and S. J. Geromano. 2006. Absolute quantification of proteins by LCMS/SE: a virtue of parallel ms acquisition. Mol. Cell Proteomics 5:144–156.

9. Serang, O., L. Moruz, M. R. Hoopmann, and L. Käll. 2012. Recognizing uncertainty increases robustness and reproducibility of mass spectrometry-based protein inferences. J. Proteome Res. 11:5586–5591.

Table 2. Receiver operating characteristics curve analysis of the proteins found to be significantly different in PC vs. CP OPLS-DA analysis and pFDR vs. VIP analysis.

| Protein Name                                         | AUC     | Lower  | Upper  | P       | Sensitivity (%) | Specificity (%) |
|------------------------------------------------------|---------|--------|--------|---------|----------------|-----------------|
| Alpha-1B-glycoprotein                                 | 0.920   | 0.827  | 1.000  | 0.000   | 82             | 92              |
| Prothrombin                                           | 0.917   | 0.818  | 1.000  | 0.000   | 86             | 83              |
| Protein AMBP                                          | 0.951   | 0.863  | 1.000  | 0.000   | 91             | 100             |
| Inter-alpha-trypsin inhibitor heavy chain H2          | 0.947   | 0.871  | 1.000  | 0.000   | 91             | 100             |
| V-type proton ATPase subunit B, kidney isof orm       | 0.939   | 0.847  | 1.000  | 0.000   | 91             | 100             |
| Hemopexin                                            | 0.886   | 0.758  | 1.000  | 0.000   | 86             | 92              |
| Pigment epithelium-derived factor                     | 0.928   | 0.837  | 1.000  | 0.000   | 86             | 92              |
| Hepatocyte growth factor-like protein                 | 0.928   | 1.000  | 0.828  | 0.000   | 100            | 83              |
| Inter-alpha-trypsin inhibitor heavy chain H1          | 0.917   | 0.825  | 1.000  | 0.000   | 77             | 100             |
| Serum amyloid P-component                             | 0.883   | 0.761  | 1.000  | 0.000   | 95             | 75              |
| Complement C3                                         | 0.909   | 0.805  | 1.000  | 0.000   | 82             | 92              |
| Acylglycerol kinase, mitochondrial                    | 0.875   | 0.756  | 0.994  | 0.000   | 82             | 83              |
| Inter-alpha-trypsin inhibitor heavy chain H3          | 0.848   | 0.690  | 1.000  | 0.001   | 86             | 83              |
| Leucine-rich repeat-containing protein 9              | 0.894   | 0.788  | 1.000  | 0.000   | 77             | 100             |
| Complement factor I                                   | 0.902   | 0.797  | 1.000  | 0.000   | 91             | 83              |
| Beta-2-glycoprotein 1                                 | 0.883   | 0.772  | 0.993  | 0.000   | 68             | 100             |
| Plasma protease C1 inhibitor                          | 0.905   | 0.800  | 1.000  | 0.000   | 86             | 92              |
| Afamin                                               | 0.894   | 0.777  | 1.000  | 0.000   | 86             | 92              |
| Lipoygenase homology domain-containing protein 1      | 0.894   | 1.000  | 0.788  | 0.000   | 95             | 67              |
| Protocadherin alpha-13                                | 0.841   | 0.703  | 0.978  | 0.001   | 86             | 83              |

Area under the curve values (AUC), lower and upper confidence values, P value, sensitivity and specificity are given in the table.
10. Di Luca, A., M. Henry, P. Meleady, and R. O’Connor. 2015. Label-free LC-MS analysis of HER2 + breast cancer cell line response to HER2 inhibitor treatment. DARU 23:40.

11. Thévenot, E. A., A. Roux, Y. Xu, E. Ezan, and C. Junot. 2015. Analysis of the human adult urinary metabolome variations with age, body mass index, and gender by implementing a comprehensive workflow for univariate and opls statistical analyses. J. Proteome Res. 14:3322–3335.

12. Benjamini, Y., and Y. Hochberg. 1995. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Series B (Methodol) 57:289–300.

13. Levin, Y., E. Hradetzky, and S. Bahn. 2011. Quantification of proteins using data-independent analysis (MSE) in simple and complex samples: a systematic evaluation. Proteomics 11:3273–3287.

14. Kamburov, A., R. Cavill, T. M. D. Ebbels, R. Herwig, and H. C. Keun. 2011. Integrated pathway-level analysis of transcriptomics and metabolomics data with iMPaLA. Bioinformatics 27:2917–2918.

15. Vizcaíno, J. A., A. Cañadas, N. del-Toro, J. A. Dianes, J. Griss, I. Lavidas, et al. 2016. 2016 update of the PRIDE database and its related tools. Nucleic Acids Res. 44:D447–D456.

16. Jemal, A., F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman. 2011. Global cancer statistics. CA Cancer J. Clin. 61:69–90.

17. Siegel, R., D. Naishadham, and A. Jemal. 2013. Cancer statistics, 2013. CA Cancer J. Clin. 63:11–30.

18. Homma, T., and R. Tsuchiya. 1991. The study of the carbohydrate antigen 19-9 as a screening test for pancreatic cancer in Japan, using CA19-9 and elastase-1 or ultrasonography. Int. J. Pancreatol. 19:182–186.

19. Kim, J.-E., J. K. Lee, S. W. Paik, J. C. Rhee, and K. C. Choi. 2004. Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. J. Gastroenterol. Hepatol. 19:182–186.

20. Poruk, K. E., D. Z. Gay, K. Brown, J. D. Mulvihill, K. M. Boucher, C. L. Scaife, et al. 2013. The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates. Curr. Mol. Med. 13:340–351.

21. Sun, B., A. G. Utleg, Z. Hu, S. Qin, A. Keller, C. Lorang, et al. 2013. Glycocapture-assisted global quantitative proteomics (gagQP) reveals multiorgan responses in serum toxicoproteome. J. Proteome Res. 12:2034–2044.

22. Hortin, G. L., and D. Sviridov. 2010. The dynamic range problem in the analysis of the plasma proteome. J. Proteomics. 73:629–636.
Supporting Information

Additional supporting information may be found in the online version of this article:

**Figure S1.** Permutation testing of significance of R²Y and Q²Y values. A. Model including all patients, B. Model excluding two suspected outlier patients. 1000 permutations were performed.

**Figure S2.** Score distance versus the orthogonal distance plot for the dataset. The score distance cutoff line is the vertical dotted line, the orthogonal distance cutoff line is the horizontal dotted line. Any sample lying to the right of the vertical line or to the top of the horizontal line can be considered as outlier.

**Figure S3.** Pathway over-representation analysis by IMPaLA. Pathway enrichment analysis using IMPaLA web based server was performed on two proteins list, one having highest mean in chronic pancreatitis (CP, left panel) and other having highest mean in pancreatic cancer (PC, right panel). P-value is given in blue bars while Q values are represented by red bars.

**Figure S4.** Molecular and cellular functions in IPA core analysis. Ingenuity pathway analysis “core analysis” was performed on the proteomic dataset and top molecular and cellular functions and disease and disorders are given here.

**Table S1.** Pancreatic cancer samples: All patients were M0, had no distant metastases.

**Table S2.** All the proteins quantified in the study with one or more unique peptides. Accession, peptide count (total peptides) and unique peptides, confidence score for identification, ANOVA p values for each protein, maximum fold change and the highest and lowest mean conditions are given in the table along with the full protein name in the description heading.

**Table S3.** Proteins included in OPLS-DA modeling post-filtering based on two unique peptides and confidence score of more than 4.5.